Collider-stratification bias arises from conditioning on a variable (collider) which opens a path from exposure to outcome. M bias occurs when the collider-stratification bias is transmitted through ancestors of exposure and outcome. Previous theoretical work, but not empirical data, has demonstrated that M bias is smaller than confounding bias. The authors simulated data for large cohort studies with binary exposure, an outcome, a collider, and 2 predictors of the collider. They created 178 scenarios by changing the frequencies of variables and/or the magnitudes of associations among the variables. They calculated the effect estimate, percentage bias, and mean squared error. M bias in these realistic scenarios ranged from −2% to −5%. When the authors increased one or both relative risks for the relation between the collider and unmeasured factors to ≥8, the negative bias was more substantial (>15%). The result was substantially biased (e.g., >20%) if an unmeasured confounder that was also a collider was not adjusted to avoid M bias. In scenarios resembling those the authors examined, M bias had a small impact unless associations between the collider and unmeasured confounders were very large (relative risk > 8). When a collider is itself an important confounder, controlling for confounding would take precedence over avoiding M bias. bias (epidemiology); simulation Abbreviations: CAD, coronary artery disease; DAG, directed acyclic graph; RR, relative risk; SSRI, selective serotonin reuptake inhibitor.
Databases with a large number of covariates are widely used in epidemiologic studies of therapeutics and other health-care interventions. Because subjects are not randomly assigned to treatment, those receiving different treatments may not be comparable in terms of various characteristics that may also affect outcomes; therefore, accounting for confounding is essential for obtaining unbiased estimates. However, these adjustments may lead to biased estimatesfor instance, if a collider or an instrumental variable is controlled by design and in the analyses (1, 2) .
Directed acyclic graphs (DAGs) are used in epidemiology to facilitate study design, aid selection of statistical analysis models, and provide a graphic framework for classifying potential sources of bias (3, 4) . Collider-stratification bias arises because of conditioning on a collider (a variable that is directly affected by 2 other variables in causal DAGs) by study design or statistical analysis, and therefore it induces a spurious statistical association between the two variables that are marginally independent (5-7). M bias (5, 6 ) is a special case in which the collider has no causal association with exposure or outcome but is indirectly associated with both through ancestors (causes) of exposure and disease ( Figure 1 ).
In some simple models, Greenland (6) showed that the magnitude of the M bias along a backdoor path opened by collider conditioning is very small relative to the direct effect along that path. Empirical studies evaluating the consequences of M bias in epidemiologic studies have not been available. Using simulated data sets, we aimed to quantify the magnitude of M bias in typical situations and to explore settings that are sufficient to give a substantial amount of M bias.
MATERIALS AND METHODS

Hypothetical studies and causal structure
We first considered 2 hypothetical pharmacoepidemiologic cohort studies with binary exposures and outcomes in persons aged ≥65 years. The first study evaluated the risk of lung cancer associated with the use of selective serotonin reuptake inhibitors (SSRIs). The second study examined lung cancer risk associated with statin use. These 2 studies represented different causal structures ( Figure 1 ). Using these specific examples allowed us to set reasonable base parameter values based on the published literature. To increase generalizability, we varied the parameters widely and added 2 more studies (see Web Appendix and Web Figure 1 , which appear on the Journal's website (http://aje. oxfordjournals.org/)) representing 2 additional causal structures for M bias. We used these simulated data sets to assess the magnitude of M bias by comparing the estimated effects with predefined true effects of treatment.
Causal diagrams for hypothetical studies Figure 1 shows DAGs for the 2 hypothetical cohort studies. DAG 1 represents the original M diagram in the theoretical work. Neither smoking nor depression is a confounder of the exposure-outcome association because, according to DAG 1, smoking or depression is not a common cause of the exposure (i.e., use of SSRIs) and the outcome (i.e., lung cancer). Coronary artery disease (CAD) is a collider of the causal pathway "lung cancer-smoking-CADdepression-SSRI use," because both depression and smoking are predictors of CAD. We assumed that depression is not a cause of lung cancer and that smokers are not more or less likely to receive SSRIs than nonsmokers. Thus, there is no direct arrow from depression to lung cancer or from smoking to SSRI use.
Statins are first-line therapy for hypercholesterolemia and are recommended for secondary prevention in patients with CAD. In DAG 2, we added an arrow from CAD to statin use ( Figure 1 ). Unlike in DAG 1, smoking is causally associated with both statin use and lung cancer. Therefore, in DAG 2, smoking is a confounder of the exposure-outcome association. Not controlling for smoking would lead to a biased estimate. The confounding can be attenuated or eliminated by adjusting for CAD in the regression model. (We assumed that information on smoking status was not collected; hence, it could not be adjusted for in the analyses.) However, the adjustment would introduce M bias by opening a backdoor path between exposure and outcome. We assumed that smoking does not cause statin use through pathways other than CAD and that hypercholesterolemia is not an independent risk factor for lung cancer.
Pearl (2, 5) and Greenland (6) discussed other M diagrams in their theoretical work. To make our empirical work more generalizable to other M diagrams, we simulated data to mimic the "bow-tie" diagram (DAG 3), in which the collider is causally associated with both exposure and outcome (Web Figure 1) . Finally, DAG 4 is a mirror image of DAG 2. Instead of having an arrow between collider and exposure, there is an arrow from the collider to the outcome (Web Figure 1) .
Data generation
We conducted Monte Carlo simulations to generate data from the causal DAGs. We made the following assumptions for the simulation exercise: 1) all variables were dichotomous following a Bernoulli distribution; 2) associations between variables were positive unless otherwise specified; and 3) the outcome was log-linearly associated with latent variables with an additive effect.
For each DAG, we simulated 1,000 data sets, each containing 100,000 subjects to minimize variability due to small samples. For DAG 1, we first independently simulated data for depression and smoking based on published literature (8, 9) . We then generated the remaining data using the following formulae:
where α 0 is the prevalence of CAD among older patients who are nonsmokers and do not have depression; θ 0 is the prevalence of SSRI users who do not have depression; and γ 0 is the risk of lung cancer among nonsmokers who have not initiated antidepressant therapy. We used logistic regression models to simulate CAD and SSRI use because of the assumption that odds ratios can approximate relative risks when the outcome is rare.
For DAG 2, we used the following formulae:
Parameter values for the basic scenario are presented in Tables 1 and 2 for DAG 1 and DAG 2, respectively. For the SSRI study (DAG 1), we assumed that 25% of the population had depression (8) and that 10% were current smokers (9) . The prevalence of CAD among patients who were nonsmokers and did not have depression was 7.6% (10). Patients with depression had a slightly higher risk of CAD (relative risk (RR) = 1.6) (11). The risk of CAD was approximately 3-fold higher among ever smokers compared with nonsmokers (12) . The prevalence of lung cancer among elderly persons who had not received SSRIs or statins was 353 per 100,000 based on Surveillance, Epidemiology, and End Results (SEER) data (13) . Depression was strongly associated with SSRI use (RR = 27) because it is one of the indications for use of these drugs (14) . The relative risk for the relation between lung cancer and smoking was fixed at 15 (15) .
For the statin study (DAG 2), we assumed that 75% of the population had hypercholesterolemia (10) . We also assumed that the relative risk for the cholesterol-CAD association was 3 (16, 17) . A study by Federman et al. (18) showed that nearly 75% of patients with CAD were taking statins 18 months after discharge. Ma et al. (19) reported that the prevalence of statin use was 10% among patients with low cardiovascular disease risk. Thus, the relative risk for the relation between CAD and statin use was set at 27 in the basic scenario.
Data-generation procedures for DAGs 3 and 4 are discussed in the Web Appendix.
Assessment of the impact of M bias
We used Poisson regression models to estimate the effect of drug exposure with or without adjusting for CAD (i.e., the collider) and other covariates in the outcome models. For the hypothetical SSRI study (DAG 1), we compared the following models:
For the statin study (DAG 2), we compared the following models:
Model 5: log e ðlung cancerÞ ¼ b 0 þ b 1 Â statins:
Models for DAGs 3 and 4 are presented in the Web Appendix. For both studies, the "causal truth" for the base case was no effect of medication use on the risk of lung cancer (20, 21) ; the true causal relative risk equaled 1. The relative risks from model 1 for DAG 1 and model 4 for DAG 2 were expected to be biased, because the collider was included in the regression models, introducing the M bias. The relative risks from model 3 for DAG 1 and model 6 for DAG 2 would be unbiased, because the M bias introduced by adjusting for the collider is blocked by including another covariate, successfully closing the backdoor path. The relative risk from model 2 for DAG 1 would be 1, because no bias was introduced. In the statin study (DAG 2), smoking is a confounder of the exposure-outcome association. Adjusting for CAD in the regression model can eliminate the confounding bias by blocking the backdoor path "lung cancer-smoking-CAD-statin use," but it simultaneously introduces M bias by opening another path, "lung cancer-smoking-CAD-hypercholesterolemia-statin use." Thus, the relative risk from model 5 (DAG 2) is expected to be biased. For both hypothetical studies, we generated data on smoking but did not include them in the regression models to represent the situation that smoking data are usually missing in databases.
For each regression model, we exponentiated the estimated median regression coefficient ðb 1 Þ to obtain the estimated c RR across 1,000 simulations. We calculated the percentage of bias using the formula ðexp Tables 1 and 2 . To explore which parameters were more influential in introducing bias, we conducted a series of simulations in various scenarios by changing one parameter at a time and keeping all others at the levels of the basic scenario. We used SAS, version 9.2 (SAS Institute Inc., Cary, North Carolina), for all data generation and analyses.
RESULTS
We simulated data sets each containing 100,000 subjects and 5 variables based on the parameter values listed in Tables 1 and 2 . For DAG 1, we generated data for the basic Abbreviations: CAD, coronary artery disease; Depre, depression; LC, lung cancer; NCI, National Cancer Institute; Pr, prevalence; Smk, smoking; RR, relative risk; SSRI, selective serotonin reuptake inhibitor.
a Pr(Depre), prevalence of depression; Pr(Smk), prevalence of current smoking; Pr(CAD), prevalence of CAD among nondepressed nonsmokers; Pr(LC), prevalence of lung cancer among nonsmokers who are untreated with SSRIs; Pr(SSRIs), prevalence of SSRI use among the nondepressed; RR (Depre-SSRIs) , RR for depression and probability of SSRI use; RR (Smk-LC) , RR for current smoking and risk of lung cancer; RR (Depre-CAD) , RR for depression and the risk of CAD; RR (Smk-CAD) , RR for current smoking and the risk of CAD; RR (SSRIs-LC), RR for SSRI use and the risk of lung cancer. a Model 1: log e (lung cancer) = β 0 + β 1 × SSRIs + β 2 × CAD, stratified on CAD (the "collider") only; thus, results would be expected to be biased. Model 2: log e (lung cancer) = β 0 + β 1 × SSRIs, the estimated marginal effect in the entire population; thus, the results would be expected to be unbiased. Model 3: log e (lung cancer) = β 0 + β 1 × SSRIs + β 2 × CAD + β 3 × depression, stratified on both depression and CAD, which blocked the "backdoor" path again; thus, results would be expected to be unbiased.
b The relative bias is defined as the difference between the estimated relative risk and the predefined true relative risk (RR = 1) divided by the true relative risk times 100; MSE is calculated as the square of the bias plus the square of the empirical standard error of the estimate over all simulations.
c The standard error is small across scenarios, ranging from 0.0013 to 0.0034. d Pr(Depre), prevalence of depression; Pr(Smk), prevalence of current smoking; Pr(CAD), prevalence of CAD among nondepressed nonsmokers; Pr(LC), prevalence of lung cancer among nonsmokers who are untreated with SSRIs; RR (Depre-CAD) , RR for depression and the risk of CAD; RR (Smk-CAD) , RR for current smoking and the risk of CAD; RR (SSRIs-LC), RR for SSRI use and the risk of lung cancer.
e For the definitions and ranges of these parameters, refer to Table 1 . Only one parameter is varied at a time, whereas all other parameters are kept constant at the level of the basic scenario presented in Table 1 (with the exception of rows for RR (SSRIs-LC) ). Note that RR (SSRIs-LC) = 1 in all scenarios, except when RR (SSRIs-LC) is the parameter varied.
scenario and 41 additional scenarios in which we changed one parameter at a time while keeping all others at their basic values (Table 3, Figure 2 ). For DAG 2, we generated simulated data sets for a total of 46 scenarios (Table 4 , Figure 3 ). Table 3 shows the estimated relative risks, the percentage bias, and the mean squared error from the 3 regression models for various scenarios for the SSRI study. As expected, the relative risks from the unadjusted model (model 2) and the model that adjusted for both CAD and depression (model 3) were unbiased (i.e., the percentage bias ranged from −0.75% to 0.55%) with a reasonable level of accuracy (the mean squared error ranged from <0.001 to 0.125). When we used the collider-only adjusted model (model 1) to analyze simulated data sets, the percentage bias was -2.08% in the basic scenario and ranged from −0.91% to −5.46% in most scenarios. The only scenario with negative bias greater than 10% (−13.14%) was the scenario in which the relative risk for the relation between depression and CAD was 10. The percentage bias did not change significantly from the basic scenario in any of the models when we changed values for the prevalence of smoking or depression, the total number of simulations conducted, or the true effect between SSRI use and lung cancer risk (Table 3) . However, the M bias induced in model 1 increased monotonically from −0.99% to −13.14% or from −1.18% to −5.46% when the relative risk for the depression-CAD or smoking-CAD relation increased. Consistent with the theoretical results (6), the M biases were all negative for the range of plausible parameter values we explored in model 1.
Results for the statin study (DAG 2) are presented in Table 4 . As expected, the treatment effect estimated by using the unadjusted model (model 5) was substantially biased (i.e., percentage bias > 20% in almost all scenarios) because of the uncontrolled confounding by CAD and/or smoking status (Table 4 ). Compared with model 5, the percentage bias due to M bias (when CAD was adjusted) with model 4 was much smaller, ranging from −1.23% to −5.32%. The estimated treatment effect was unbiased ( percentage bias, -0.51% to 0.63%) when we controlled for both CAD and hypercholesterolemia (yes/no) in the regression model (model 6). When we changed the prevalence of hypercholesterolemia, the prevalence of smoking, or the strength of the association between statin use and lung cancer, the percentage bias changed slightly compared with that obtained in the basic scenario (Table 4 ). The negative collider stratification bias was largest (i.e., percentage bias = −5.32%) when the relative risk for the relation between CAD and smoking became large (RR = 10).
We further explored situations in which substantial bias arose by simultaneously increasing both relative risks between CAD and predictors of CAD from 2 to 16 (Figures 2 and 3 ). We observed a monotonic but more dramatic increase in the negative bias in both DAG 1 and DAG 2. In the SSRI study (DAG 1), bias was −1.86% when the relative risks for depression-CAD and smoking-CAD were both set to 2. The percentage bias increased to −10.15% (Figure 2 ) when the relative risks for both depression-CAD and smoking-CAD were 4. The percentages of bias were −22.45% and −33.73% when the relative risks were 8 and 16, respectively (Figure 2 ). In the statin study, the percentages of bias were −0.87%, −3.87%, −8.35%, and −13.25% when the relative risks for both cholesterol-CAD and smoking-CAD were 2, 4, 8, and 16, respectively (Figure 3) . Similar to our observation in DAG 2, the unadjusted model was most biased due to confounding in DAGs 3 and Figure 2 . The strengths of the associations between depression and coronary artery disease (CAD) and ever smoking and CAD and the percentage of bias due to M bias, assuming that the first directed acyclic graph (DAG 1) was the causal diagram (see Figure 1) . For details about the data simulation procedure and parameter values, refer to the Materials and Methods section of the text and Table 1 . Data analysis model: log e (lung cancer) = β 0 + β 1 × SSRIs + β 2 × CAD. (RR, relative risk; SSRIs, selective serotonin reuptake inhibitors).
Simulation Study of M Bias 943 4; the model that adjusted for the collider eliminated the confounding bias but introduced a small M bias. Finally, the model that adjusted for both the collider and a predictor of the collider produced unbiased estimates (see Web  Tables 1 and 2 and Web Figures 2 and 3) .
DISCUSSION
In simulated data sets mimicking large cohort studies, we demonstrated that adjusting for a collider in regression models could result in biased estimates but that the bias was generally small unless the associations between unmeasured confounders and the collider were consistently very large (e.g., RR > 8). We also found that confounding bias was much larger than M bias in the scenarios we explored.
Our simulation results were consistent with previous theoretical work by Greenland (6) and Cole et al. (23) suggesting that conditioning on a common effect of 2 variables can introduce bias but the size of the bias is small relative to conventional confounding bias. Our empirical investigation also confirmed that the magnitude of M bias depends on the magnitude of component bias (6) . We observed that all relations between the component variables need to be very strong in order for M bias to be substantial. For example, in the base scenario for DAG 1, when all relative risks between variables were 8, the estimated relative risk analyzed using model 1 was 0.996, with a percentage bias of -0.36%. Assuming that the associations between all variables (R) were 8, the lower bound for the collider-only adjusted estimate would be 0.813 if we applied Greenland's formula (16R(R + 1) 2 /(R 2 + 16R + 1)
2 ) to quantify the amount of bias. Hence, our result is consistent with Greenland's assessment (6) .
In our stimulation study, M bias was attenuated or eliminated by closing the backdoor path through additional adjustment for other independent pretreatment covariates on the M pathway. In practice, conditioning on a collider may be inevitable (especially when the collider is a potential confounder), and variables that are required to close the backdoor path, such as smoking status, may be unmeasured. We illustrated this phenomenon in model 4 for the statin study (DAG 2), in which the collider was adjusted to Table continues 944 Liu et al.
control confounding bias and induced M bias simultaneously. In this example, we found that the magnitude of M bias was much smaller than confounding bias, because the relative risks for hypercholesterolemia-CAD and smoking-CAD were small compared with the relative risks for CAD-statin and smoking-lung cancer (Table 4) . Thus, our simulation study provides empirical evidence for the practical implication that analysts should consider all important potential confounders to control for confounding in many circumstances for observational studies.
For the examples in which we assumed binary covariates, positive associations between variables, and a log-linear association between outcome and explanatory variables, we unanimously observed a negative bias due to adjusting for the collider (i.e., CAD) in regression models. This negative bias may explain why some studies (24, 25) found a protective effect of statin use on lung cancer whereas others did not (26) (27) (28) . However, as other investigators have noted, the direction of the M bias can be either upward or downward (29)-for example, if functional forms other than an additivelinear association were allowed for modeling the exposureoutcome relation. We observed positive bias when we included a negative linear term for the association between the collider and a predictor of the collider (Tables 3 and 4) .
As was shown in our study, in nonexperimental studies, inferences may be highly dependent on which set of variables is considered for adjustment. Propensity score analysis including a large number of covariates may improve confounding control, particularly if the outcome is rare (30, 31) , but such methods may increase bias and variance relative to more parsimonious models by including biasincreasing variables such as colliders and instrumental variables (32, 33) . In addition to the M bias considered in this paper, the inclusion of instrumental variables can also amplify bias from residual confounding. This effect, which has been termed Z-bias (32), has been described theoretically (34, 35) . The bias amplification increases with the strength of the instrument, and thus is potentially problematic when strong instruments are included in models that are subject to substantial residual confounding. a Model 4: log e (lung cancer) = β 0 + β 1 × statin + β 2 × CAD, stratified on CAD (the "collider") only; thus, results would be expected to be biased. Model 5: log e (lung cancer) = β 0 + β 1 × statins, since smoking is a common cause of the exposure-outcome association; failure to adjust for smoking in model 5 would bias the effect estimate. Model 6: log e (lung cancer) = β 0 + β 1 × statins + β 2 × CAD + β 3 × hypercholesterolemia, stratified on both CAD (the "collider") and hypercholesterolemia; the "backdoor" path was closed again, and thus results would be expected to be unbiased.
b Relative bias is defined as the difference between the estimated relative risk and the predefined true relative risk (RR = 1) divided by the true relative risk times 100. MSE is calculated as the square of bias plus the square of the empirical standard error of the estimate over all simulations.
c The standard error is small across scenarios, ranging from 0.0012 to 0.0036. d Pr(HC), prevalence of subjects with hypercholesterolemia; Pr(Smk), prevalence of current smoking; Pr(CAD), prevalence of CAD among nonsmokers who do not have hypercholesterolemia; Pr(LC), prevalence of lung cancer among nonsmokers who are untreated with statins; RR (HC-Statins) , RR for hypercholesterolemia and statin use; RR (HC-CAD) , RR for hypercholesterolemia and CAD; RR (Smk-CAD) , RR for current smoking and the risk of CAD; RR (Statins-LC) , RR for statin use and the risk of lung cancer; RR (CAD-Statins) , RR for CAD and statin use.
e For the definitions and ranges of these parameters, refer to Table 2 . Only one parameter is varied at a time, whereas all other parameters are kept constant at the level of the basic scenario presented in Table 2 (with the exception of rows for RR (Statins-LC) ). Note that RR (Statin-LC) = 1 in all scenarios, except when RR (Statin-LC) is the parameter varied.
In the causal structures and parameters considered, we found that the bias would generally be more substantial for confounding than for M bias. However, we also explored scenarios in which the M bias was larger than the bias due to residual confounding (data not shown). We found that, in order for M bias to be larger than confounding bias in DAG 2, the relative risk for the cholesterol-CAD relation must be unrealistically large, whereas the relative risk for the relation between CAD and statin use must be small. For example, when the relative risk for the hypercholesterolemia-CAD relation was 50, the relative risk for the smoking-CAD relation was 15, and the relative risk for the CAD-statin relation was 2, the magnitude of the bias due to confounding was slightly smaller (6.2%) than the magnitude of the bias due to collider stratification (−7.8%).
We acknowledge several limitations. First, caution should be taken in making generalizations from the results of a simulation study. In order to demonstrate the impact of M bias, we applied simplified causal diagrams. In reality, nonexperimental studies conducted in large databases can involve many more variables with complicated causal diagrams. In addition, there is no way to tell from the data alone the underlying true causal structure (M bias, "bow-tie," an instrumental variable situation, or classical confounding). When the underlying causal diagrams are unknown, nonparsimonious regression models may be preferred despite the risk of introducing M bias, as we have shown in the simulation study. Thus, predicting the direction and magnitude of M bias would be extremely difficult with more complicated underlying causal diagrams. Second, comparing the estimated coefficients from the conditional models with results obtained from unconditional models is inappropriate. The unadjusted model estimates the marginal effect of treatment in the entire study population, whereas the conditional model estimates the effect conditional on the variables included in the regression model. Furthermore, when the data are sparse and the outcome is modeled with logistic regression, the increased estimates upon adjustment may completely or only partially reflect sparsedata bias. Third, we have not explored implications for other analytic methods (i.e., propensity score methods), which are becoming increasingly popular in database studies.
Any epidemiologic study is subject to M bias as far as the data structure comprises an M diagram and the collider is falsely controlled by design or in analyses. Although we used examples from pharmacoepidemiologic database studies to create realistic scenarios with plausible parameters, the principles we found would be applicable to many epidemiologic studies in other areas. To enhance its applicability, our simulation included 4 scenarios based on different M diagrams and used a wide range of parameter values. Large databases may naturally contain a mixture of different causal structures; consequently, study validity might be harmed because some study designs or statistical adjustment may introduce M bias.
Using Monte Carlo simulations, we demonstrated that M bias was not substantial enough to change the effect estimates meaningfully in scenarios explored in the simulation experiments, except when associations between variables were large (i.e., RR > 8). We also found that M bias was small relative to conventional confounding. Therefore, when a collider is itself an important confounder, controlling for confounding by the collider would take precedence over avoiding M bias by adjusting for the collider.
